Should Rituximab Be Used to Prevent Relapse in Patients with ANCA-Associated Vasculitis? | Zendy

Stephen P. McAdoo | Zendy; Charles D. Pusey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Should Rituximab Be Used to Prevent Relapse in Patients with ANCA-Associated Vasculitis?

Author(s) -

Stephen P. McAdoo,

Charles D. Pusey

Publication year - 2014

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.01270214

Subject(s) - rituximab , medicine , maintenance therapy , anca associated vasculitis , cyclophosphamide , vasculitis , disease , randomized controlled trial , intensive care medicine , oncology , pediatrics , surgery , chemotherapy , lymphoma

Rituximab is now licensed, both in the United States and Europe, for use as a remission-induction agent in the treatment of ANCA-associated vasculitis (AAV). Although the two randomized controlled trials on which this licensure is based did not demonstrate, at least in patients presenting with new

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research